^
BIOMARKER:
HRD
i
Other names: Homologous Recombination Deficiency
Related biomarkers:
HRD
Fallopian Tube Cancer
olaparib + bevacizumab
Sensitive
:
C1
HRD
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
C1
HRD
Peritoneal Cancer
niraparib
Sensitive
:
C1
HRD
Fallopian Tube Cancer
niraparib
Sensitive
:
C1
HRD
Ovarian Cancer
olaparib + bevacizumab
Sensitive
:
C1
HRD
Ovarian Cancer
niraparib
Sensitive
:
C1
HRD
Prostate Cancer
olaparib
Sensitive
:
C1
HRD
Ovarian Cancer
olaparib
Sensitive
:
C1
HRD
Ovarian Cancer
rucaparib
Sensitive
:
B
HRD
Ovarian Cancer
ABT-888
Sensitive
:
B
HRD
Ovarian Cancer
atezolizumab
Resistant
:
B
HRD
Ovarian Cancer
CPB
Sensitive
:
B
HRD
Triple Negative Breast Cancer
olaparib
Sensitive
:
C1
HRD
Ovarian Cancer
tislelizumab + BGB-290
Sensitive
:
C2
HRD
Triple Negative Breast Cancer
tislelizumab
Sensitive
:
C2
HRD
Ovarian Cancer
bevacizumab + niraparib
Sensitive
:
C2
HRD
NSCLC
talazoparib
Resistant
:
C3
HRD
Gastric Cancer
nivolumab
Sensitive
:
C3
HRD
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive
:
C3
HRD
Prostate Cancer
nivolumab + ipilimumab
Sensitive
:
C3
HRD
Prostate Cancer
abiraterone acetate
Resistant
:
C3
HRD
Ovarian Cancer
ABT-767
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our